Makris M, Colvin B, Gupta V, Shields M L, Smith M P
Sheffield Haemophilia and Thrombosis Centre, Royal Hallamshire Hospital, UK.
Thromb Haemost. 2002 Sep;88(3):387-8.
We describe four patients with von Willebrand's disease (VWD) who experienced venous thrombosis after treatment with an intermediate purity factor VIII (FVIII) concentrate (Haemate P3) was used to cover invasive or surgical procedures. Most patients had additional risk factors for venous thromboembolism (VTE) and it is difficult to be certain of the contribution of the concentrate to the VTE. In view of the recognised association between high factor VIII activity (FVIII:C) levels and VTE there is a physiological basis for this complication and it is important to consider this when administering FVIII containing concentrates to VWD patients.
我们描述了4例血管性血友病（VWD）患者，他们在使用中间纯度的凝血因子VIII（FVIII）浓缩物（Haemate P3）进行侵入性或外科手术治疗后发生了静脉血栓形成。大多数患者有静脉血栓栓塞（VTE）的其他危险因素，很难确定浓缩物对VTE的影响。鉴于已认识到的高凝血因子VIII活性（FVIII:C）水平与VTE之间的关联，这种并发症有生理基础，在给VWD患者使用含FVIII的浓缩物时考虑这一点很重要。
